What Has Been the Growth of the Pediatric Drugs Market So Far?
The pediatric drugs market has seen considerable growth due to a variety of factors.
• The market for pediatric drugs has seen swift expansion in the past few years. Its growth is expected to continue, rising from $157.0 billion in 2024 to $181.02 billion in 2025, representing a compound annual growth rate (CAGR) of 15.3%.
This significant uptick during the historic period can be accounted for by the rising demand for corresponding pharmaceuticals, the expanding pediatric population, heightened awareness of pediatric illnesses, the growth of pediatric oncology as a discipline, the emergence of digital health and telemedicine, as well as the increased partnership in the development of pediatric drugs.
What Are the Future Growth Projections for the Pediatric Drugs Market?
The pediatric drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for pediatric drugs is predicted to experience significant expansion in the coming years, reaching $316.0 billion by 2029 with a compound annual growth rate (CAGR) of 14.9%.
This prospective growth within the forecast period is linked to an increasing number of children, growing concerns of mental health issues among children, a surge in chronic conditions in children, an increase in childhood vaccination, and a rising demand for pediatric mental health medications. Notable trends during the forecast period encompass personalized pediatric medicine, tech advancements in child drug administration, the use of telemedicine and digital health solutions, improved pediatric clinical trials, and collaborations between pediatricians and pharmacists.
What Are The Core Factors Supporting Growth In The Pediatric Drugs Market?
The pediatric drugs market is predicted to expand due to a rise in preterm births. Preterm births are births that happen before 37 weeks of pregnancy, earlier than the usual gestational period of 40 weeks. This increase in preterm births can be credited to several factors including advanced maternal age, lifestyle decisions, health conditions, multiple pregnancies, and insufficient prenatal care. Pediatric drugs are crucial for supporting the health and growth of preterm babies by providing targeted solutions for issues like respiratory complications, infections, and nutritional deficiencies. For example, a report from Tommy's, a UK-based charitable organization, revealed that the rate of premature live births in England and Wales rose to 7.9% in December 2022, from 7.5% in 2021, indicating over 53,000 premature births in 2022. Hence, the escalating number of preterm births is propelling the pediatric drugs market's growth.
What Are The Major Segments Within The Global Pediatric Drugs Market?
The pediatric drugs market covered in this report is segmented –
1) By Type: Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs
2) By Route Of Administration: Oral, Topical, Parenteral, Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Respiratory Disorder Drugs: Asthma Medications, Cystic Fibrosis Treatments, Bronchodilators, Corticosteroids
2) By Autoimmune Disorder Drugs: Immunosuppressants, Biologic Therapies, Disease-Modifying Antirheumatic Drugs (DMARDs)
3) By Gastrointestinal Drugs: Proton Pump Inhibitors (PPIs), Antiemetics, Antidiarrheals, Laxatives
4) By Cardiovascular Drugs: Antihypertensive Medications, Heart Failure Treatments, Antiarrhythmic Drugs, Lipid-lowering Agents
Pre-Book The Pediatric Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Pediatric Drugs Market?
Top corporations in the pediatric drugs market are putting their focus on the creation of unique drugs, like fully human monoclonal antibodies, with the aim of enhancing the prognosis and minimizing negative effects for children who are patients. A fully human monoclonal antibody (mAb) is completely derived from human genetic codes, reducing potential immune system reactions relative to chimeric or humanized monoclonal antibodies. These mAbs are created with sophisticated biotechnological methods, such as transgenic mice engineered with human antibody genes or the use of phage showcase technology. For instance, in August 2022, Johnson and Johnson, a pharmaceutical giant from the United States, earned the FDA's approval for their drug STELARA (ustekinumab) to treat pediatric patients aged six years and above who are suffering from active psoriatic arthritis (PsA). This milestone is significant because STELARA is the first and exclusive biologic formula that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), essential cytokines involved in inflammatory reactions linked to autoimmune diseases. Active PsA is a rarely seen disorder that affects around 5-8% of children diagnosed with long-term inflammatory arthritis, causing symptoms that include swelling of the joints and skin lesions.
Who Are the Key Players In The Pediatric Drugs Market?
Major companies operating in the pediatric drugs market are:
• Pfizer Inc.
• Johnson & Johnson
• Merck & Co. Inc.
• Bayer AG
• Sanofi S.A.
• Bristol-Myers Squibb
• AstraZeneca Plc
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company
• Eli Lilly and Co.
• Gilead Sciences Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Vertex Pharmaceuticals
• UCB Pharma
• Sun Pharmaceutical Industries Ltd.
• Perrigo Company
• Shionogi & Co. Ltd.
• Mallinckrodt
• Torrent Pharmaceuticals Ltd
• Sarepta Therapeutics
• Zydus Cadila
What Is The Most Dominant Region In The Pediatric Drugs Market?
North America was the largest region in the pediatric drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
